Meal-dependent regulation of circulating glycated insulin in type 2 diabetic subjects

Hormone and Metabolic Research

Volumn 38, Issue 2, 2006, Pages 94-97

  McKillop, Aine M ^a   Lindsay, J R ^b   Au, S ^b   Mahood, K I ^a   O'Harte, F P M ^a   Flatt, P R ^a   Bell, P M ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Glycated insulin; Meal; Type 2 diabetes

Indexed keywords

C PEPTIDE; CARBOHYDRATE; GLYCATED INSULIN; INSULIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DIET; ENTERIC FEEDING; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; FOOD; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; TIME FACTORS;

EID: 33645721086     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-925125     Document Type: Article

References (29)

1. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: Implications of the management of diabetes. Diabetologia 1985; 28: 119-121
2. Leahy JL. B-cell dysfunction with chronic hyperglycaemia: overworked beta cell hypothesis. Diabetes Revs 1996; 4: 298-319
3. Sato E, Mori F, Igarashi S, Abiko T, Takeda M, Ishika S, Yoshida A. Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 2001; 24: 479-482
4. Schinzel R, Munch G, Heidland A, Sebekova K. Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001; 87: 295-303
5. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000; 37: 87-92
6. Brownlee M. Glycation and diabetic complications. Diabetes 1993; 43: 836-841
7. Lyons TJ, Jenkins AJ. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Reviews 1997; 5: 365-391
8. Eizirik EL, Korbutt GS, Hellerstrom C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the β-cell function. J Clin Invest 1992; 90: 1263-1268
9. Svensson C, Sandler S, Hellerstrom C. Lack of long term β-cell glucotoxicity in vitro in pancreatic islets isolated from two mouse strains (C57BL/6J; C57BL/KsJ) with different sensitivities of the β-cells to hyperglycaemia in vivo. J Endocrinol 1993; 136: 289-296
10. McKillop AM, Abdel-Wahab YHA, Mooney MH, O'Harte FPM, Flatt PR. Secretion of glycated insulin from pancreatic B-cells in diabetes represents a novel aspect of B-cell dysfunction and glucose toxicity. Diabetes and Metabolism 2002; 28: 3S61-3S69
11. Oda A, Bannai C, Yamaoka T, Katori T, Matsushima T, Yamashita K. Inactivation of Cu, Zn-superoxide dismutase by in vitro glycosylation and in erythrocytes of diabetic patients. Horm Metab Res 1994; 26: 1-4
12. O'Harte FPM, Abdel-Wahab YHA, Conlon JM, Flatt PR. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim Biophys Acta 1998; 1425: 319-327
13. O'Harte FPM, Mooney MH, Kelly CM, Flatt PR. Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes 1998; 47: 1619-1624
14. Abdel-Wahab YHA, O'Harte FPM, Barnett CR, Flatt PR. Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture. J Endocrinol 1997; 152: 59-67
15. Abdel-Wahab YHA, O'Harte FPM, Boyd AC, Barnett CR, Flatt PR. Glycation of insulin results in reduced biological activity in mice. Acta Diabetol 1997; 34: 265-270
16. McKillop AM, Mooney MH, Harriott P, Flatt PR, O'Harte FPM. Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay. Biochem Biophys Res Comm 2001; 286: 524-528
17. Lapolla A, Tessari P, Poli T, Valerio A, Duner E, Iori E, Fedele D, Crepaldi G. Reduced in vivo biological activity of in vitro glycosylated insulin. Diabetes 1988; 37: 787-791
18. Boyd AC, Abdel-Wahab YHA, McKillop AM, McNulty H, Barnett CR, O'Harte FPM, Flatt PR. Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. Biochim Biophys Acta 2000; 1519: 128-134
19. Hunter SJ, Boyd AC, O'Harte FPM, McKillop AM, Wiggam MI, Ennis CN, Gamble R, Sheridan B, Barnett CR, McNulty H, Bell PM, Flatt PR. Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic hyperinsulinemic clamp technique in man. Diabetes 2003; 52: 492-498
20. McKillop AM, McCluskey JT, Boyd AC, Mooney MH, Flatt PR, O'Harte FPM. Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues. J Endocrinol 2000; 167: 153-163
21. Lindsay JR, McKillop AM, Mooney MH, O'Harte FPM, Bell PM, Flatt PR. Demonstration of elevated concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay. Diabetologia 2003; 46: 475-478
22. Lindsay JR, McKillop AM, Mooney MH, Flatt PR, Bell PM, O'Harte FPM. Meal-induced twenty-four hour profile of circulating glycated insulin in type 2 diabetic subjects measured by a novel radioimmunoassay. Metabolism 2003; 52: 631-635
23. Salacinski PR, McLean C, Sykes JE, Clement-Jones W, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha, 6 alpha-diphenyl glycoluril (iodogen). Anal Biochem 1981; 117: 136-146
24. Stevens JF. Determination of glucose by an automatic analyser. Clin Chim Acta 1971; 32: 199-201
25. The Diabetes Control and Complications Trial Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 1987; 10: 1-19
26. Abdel-Wahab YHA, O'Harte FPM, Ratcliff H, McClenaghan NH, Barnett CR, Flatt PR. Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes 1996; 45: 1489-1496
27. Lindsay JR, McKillop AM, Mooney MH, O'Harte FPM, Flatt PR, Bell PM. The effect of nateglinide on the secretion of glycated insulin and glucose intolerance in type 2 diabetes. Diabetic Research and Clinical Practice 2003; 61: 167-173
28. Green BD, Gault VA, O'Harte, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 2004; 10: 3651-3662
29. Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 2004; 53: 2359-2365